Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 111 Matches

5HMT_V12R2_USFDA_20160510
Metabolite of fesoterodine. Note/correction: 1. PKa 9.3 instead of 7.6 (in supplemental materials) 2. the intrinsic clearance (CLint) values of CYP3A4 and CYP2D6 should be 0.085 and 1.455 uL/min/pmol enzyme 3. note simulation with ketoconazole, ketoconazole cmp file modified with p-gp inhibition constant (Ki) of 0.015 uM (assumed)
EsomeprazoleCapsule_V14R1_AstraZeneca_20200427
https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.905 Esomeprazole adult compound file for pediatric prediction. The following parameters need to be updated, as compared to Table 2 in the manuscript: Ka=1.331/h, tlag=1h, fu,gut=0.048
Tizanidine_V18R1_LongIslandUniversity_20210119
This is compound file for tizanidine, a CYP1A2 substrate. The input values for the Tizanidine PBPK model are listed in table 1 of the publication. The file uses a User fugut of 1E-06. A solid formulation is used with the segregated transit time model activated and a predicted aqueous phase intrinsic solubility.
Pemigatinib_V19R1_Incyte_20220114
A Pemigatinib PBPK article accepted by CPT PSP with leading author as Tao Ji The submitted workspace files for Pemigatinib is using minimal PBPK model with ADAM functions for Pemigatinib that incorporates CYP3A4-mediated metabolism derived from in vitro data, mass balance data, and clinical PK data, for the purpose of evaluation of clinical DDIs with strong CYP3A inhibitors and/or inducers.

|<

<

15

16

17

18

19

20

21

22

23

24

25

26

27

28

>

>|